2,670,523 Shares in Organon & Co. $OGN Bought by Kahn Brothers Group Inc.

Kahn Brothers Group Inc. acquired a new stake in shares of Organon & Co. (NYSE:OGN) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,670,523 shares of the company’s stock, valued at approximately $36,159,000. Organon & Co. makes up approximately 0.1% of Kahn Brothers Group Inc.’s investment portfolio, making the stock its 17th biggest holding. Kahn Brothers Group Inc. owned about 1.02% of Organon & Co. as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in OGN. Vanguard Group Inc. grew its position in shares of Organon & Co. by 2.7% in the 4th quarter. Vanguard Group Inc. now owns 36,916,382 shares of the company’s stock worth $264,690,000 after buying an additional 987,979 shares during the last quarter. State Street Corp lifted its position in Organon & Co. by 2.8% during the fourth quarter. State Street Corp now owns 9,597,761 shares of the company’s stock valued at $68,816,000 after acquiring an additional 262,185 shares during the last quarter. AQR Capital Management LLC lifted its position in Organon & Co. by 105.2% during the fourth quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock valued at $61,282,000 after acquiring an additional 4,394,814 shares during the last quarter. Private Management Group Inc. boosted its stake in Organon & Co. by 38.3% in the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock valued at $31,169,000 after acquiring an additional 1,204,979 shares in the last quarter. Finally, UBS Group AG boosted its stake in Organon & Co. by 55.2% in the fourth quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after acquiring an additional 1,527,492 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Performance

Shares of Organon & Co. stock opened at $13.77 on Friday. The company has a 50 day moving average price of $13.58 and a 200 day moving average price of $11.07. The firm has a market capitalization of $3.61 billion, a P/E ratio of 17.88, a PEG ratio of 1.27 and a beta of 1.55. The company has a quick ratio of 1.44, a current ratio of 1.95 and a debt-to-equity ratio of 8.43. Organon & Co. has a 52 week low of $5.69 and a 52 week high of $13.77.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Organon & Co.’s payout ratio is presently 10.39%.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. Five research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $11.40.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.